We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Yervoy

News List

Bristol-Myers Squibb beats Street revenue, EPS estimates in Q4 as Eliquis surges fiercepharma
February 06, 2018
The same day Bristol-Myers Squibb reported a closely watched trial win for cancer combo Opdivo-plus-Yervoy in certain lung cancer patients, the drugmaker announced 2017 results, beating expectations with Opdivo and anticoagulant Eliquis.
Bristol-Myers Squibb's Yervoy scores EU approval in paediatric melanoma pharmafile
January 24, 2018
Bristol-Myers Squibb has revealed that its immunotherapy Yervoy has received an expanded indication from the European Commission, approving the drug for use in the European Union in the treatment of advanced melanoma in paediatric patients 12 years of ag
Mixed results for BMS’ Opdivo, Yervoy combo in kidney cancer pharmatimes
August 17, 2017
A combination of Bristol-Myers Squibb’s Opdivo and Yervoy has failed to significantly improve progression-free survival (PFS) compared to Pfizer’s Sutent in patients with renal cancer.

Previous page 1 2 3 Next page